Click Therapeutics
Click Therapeutics Leadership & Management
What People Are Saying About Click Therapeutics
-
Strategic Vision & Planning: Public communications repeatedly frame a two‑pillar strategy—stand‑alone prescription digital therapeutics and “Software‑Enhanced Drugs”—with consistent messaging from the founder‑CEO and strategy leaders, reinforced by branding updates and partner announcements. Milestones such as the April 2025 FDA authorization of CT‑132 and the March 2025 Medidata/Dassault partnership align execution with this stated plan.
-
Strong Execution: Documented outcomes include FDA marketing authorization for CT‑132 (episodic migraine) and continued partnering activity like the January 2026 Ultrahuman collaboration. Investor and company communications also cite recent executive and board build‑out to support pharma‑grade partnerships.
-
Collaborative & Aligned Leadership: The C‑suite spans technology, clinical/evidence generation, commercial, legal/privacy, people, finance, and strategy, indicating cross‑functional coverage suited to regulated software therapies. External directories largely corroborate the core lineup published on the company’s site, suggesting organizational alignment around this leadership group.
Click Therapeutics's Benefits
Hosts in-person all-hands meetings
Implements team-based strategic planning
Open office floor plan to encourage communication and collaboration
Uses an OKR operational model to clearly define goals and priorities
Utilizes an open door policy that encourages accessibility
